Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

Slides:



Advertisements
Similar presentations
Blood Pressure Control is an Independent Predictor of Short-term Mortality in Cardiac Surgery Patients: Solomon Aronson, M.D. FACC,FCCP,FAHA,FASE Professor.
Advertisements

V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Clinical Outcomes with Newer Antihyperglycemic Agents
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Meredith Cook – PharmD Candidate Mercer University COPHS August, 2012 Cognitive Trajectories after Postoperative Delirium.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Blood Pressure Control with Clevidipine Compared with Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Peri-operative Hypertension:
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Oncology Institute of Vojvodina Department of anaesthesiology and intensive care Institutski put 4, Sremska Kamenica, SERBIA
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Clinical Outcomes with Newer Antihyperglycemic Agents
Clinical Outcomes with Newer Antihyperglycemic Agents
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
The SPRINT Research Group
ACCORD Design and Baseline Characteristics
Blood Pressure and Age in Controlling Hypertension
Vanguard Phase Results for the Blood Pressure Component
First time a CETP inhibitor shows reduction of serious CV events
Traditional parenteral antihypertensive treatment
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
Management of perioperative hypertension
The Hypertension in the Very Elderly Trial (HYVET)
Section 7: Aggressive vs moderate approach to lipid lowering
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Atlantic Cardiovascular Patient Outcomes Research Team
A Target for Perioperative Blood Pressure During Cardiac Operations
Presentation transcript:

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold H. Levy Presented at the American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

Background Perioperative blood pressure (BP) variability during cardiac surgery and intraoperative hemodynamic abnormalities may be associated adverse outcome including death, stroke, renal dysfunction, perioperative myocardial infarction (MI), and increased mortality in this patient population Perioperative blood pressure (BP) variability during cardiac surgery and intraoperative hemodynamic abnormalities may be associated adverse outcome including death, stroke, renal dysfunction, perioperative myocardial infarction (MI), and increased mortality in this patient population Up to 86% of cardiac surgery patients require intravenous (IV) therapy to actively manage BP Up to 86% of cardiac surgery patients require intravenous (IV) therapy to actively manage BP Anesth Analg 2002:94; Anesth Analg 2002:95; Circulation 2007:115; Hypertension 2007;50: Anesth Analg 2008:107;1122-9, 2008

Background The Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (ECLIPSE) program was performed to compare the safety and efficacy of clevidipine butyrate intravenous emulsion (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery The Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (ECLIPSE) program was performed to compare the safety and efficacy of clevidipine butyrate intravenous emulsion (CLV) with nitroglycerin (NTG), sodium nitroprusside (SNP), and nicardipine (NIC) in the treatment of perioperative acute hypertension in patients undergoing cardiac surgery In ECLIPSE, poor perioperative BP control was a significant predictor of 30-day mortality In ECLIPSE, poor perioperative BP control was a significant predictor of 30-day mortality –Patients with poor blood pressure (BP) control are at higher risk of 30-day death, stroke, myocardial infarction (MI), and renal dysfunction compared with those with tight control (P<0.01, odds ratio 1.003, 95% confidence interval 1.001–1.004) –In other words, the worse the blood pressure control, the worse the outcome

Methods In the present study, data from the ECLIPSE program were examined further to determine whether the risk of 30-day adverse clinical outcomes (death, MI, stroke, and renal dysfunction) increased as systolic BP (SBP) became progressively more labile outside of a preselected BP target range In the present study, data from the ECLIPSE program were examined further to determine whether the risk of 30-day adverse clinical outcomes (death, MI, stroke, and renal dysfunction) increased as systolic BP (SBP) became progressively more labile outside of a preselected BP target range The ECLIPSE program comprised 3 prospective, randomized, open-label, parallel comparison studies of CLV to NTG or SNP perioperatively, or NIC postoperatively in patients undergoing cardiac surgery at 61 medical centers The ECLIPSE program comprised 3 prospective, randomized, open-label, parallel comparison studies of CLV to NTG or SNP perioperatively, or NIC postoperatively in patients undergoing cardiac surgery at 61 medical centers Of the 1964 patients enrolled, 1512 met post randomization inclusion criteria of requiring acute treatment of hypertension based on clinical determination (modified intent-to-treat population) Of the 1964 patients enrolled, 1512 met post randomization inclusion criteria of requiring acute treatment of hypertension based on clinical determination (modified intent-to-treat population) –Five were not included due to missing or incomplete area under the curve (AUC) data, for a total of 1507 patients

Methods The efficacy of CLV versus comparator drugs for the treatment of acute hypertension was assessed using AUC analysis of BP excursions beyond predetermined upper and lower limits, normalized per hour (AUCSBP-D) The efficacy of CLV versus comparator drugs for the treatment of acute hypertension was assessed using AUC analysis of BP excursions beyond predetermined upper and lower limits, normalized per hour (AUCSBP-D) –These ranges, chosen to reflect standard clinical practice and predefined for analysis purposes, were 65 to 135 mm Hg intraoperatively (from chest incision through chest closure) and 75 to 145 mm Hg pre- and postoperatively In a posthoc analysis, patients were grouped into quartiles (Qs 1–4) as defined by BP lability (Q4 was most labile and Q1 least labile) In a posthoc analysis, patients were grouped into quartiles (Qs 1–4) as defined by BP lability (Q4 was most labile and Q1 least labile)

Methods The primary outcome was the incidence of death, MI, stroke, or renal dysfunction at 30 days as assessed by the Clinical Endpoints Committee The primary outcome was the incidence of death, MI, stroke, or renal dysfunction at 30 days as assessed by the Clinical Endpoints Committee Perioperative BP was controlled from preincision through the perioperative period with CLV (2–16 mg/h titrated to BP-lowering effect) versus a comparator (IV NTG, SNP, or NIC), dosed according to institutional practice Perioperative BP was controlled from preincision through the perioperative period with CLV (2–16 mg/h titrated to BP-lowering effect) versus a comparator (IV NTG, SNP, or NIC), dosed according to institutional practice –Patients were randomized 1:1 to study drugs

ECLIPSE Patient Characteristics AUC Study Population (N=1507) Quartile 1 AUC 0–<0.09 (n=376) Quartile 2 AUC 0.09–<4.77 (n=377) Quartile 3 AUC 4.77–<26.21 (n=377) Quartile 4 AUC ≥26.21 (n=377)P Value Median age, years (IQR) 63.0 (56.0, 72.0) 65.0 (57.0, 72.0) 66.0 (58.0, 73.0) 67.0 (60.0, 75.0) < Male, n (%)279 (74.2) 289 (76.7) 277 (73.5) 260 (69.0) White, n (%)323 (85.9) 331 (87.8) 312 (82.8) 277 (73.5) < Median BMI, kg/m2 (IQR) 28.7 (25.6, 32.4) 28.7 (25.8, 32.2) 29.3 (25.7, 32.8) 28.0 (24.9, 31.5) Screening SBP >160 or DBP >105, n (%) 29 (7.7) 55 (14.6) 81 (21.5) < History of hypertension, n (%) 306 (81.4) 323 (85.7) 324 (85.9) 343 (91.0) CHF, n (%)71 (18.9) 50 (13.3) 71 (18.8) 86 (22.8) COPD, n46 (12.2) 65 (17.2) 55 (14.6) 52 (13.8) Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

ECLIPSE Patient Characteristics AUC Study Population (N=1507) Quartile 1 AUC 0–<0.09 (n=376) Quartile 2 AUC 0.09–<4.77 (n=377) Quartile 3 AUC 4.77–<26.21 (n=377) Quartile 4 AUC ≥26.21 (n=377)P Value Diabetes, n119 (31.6) 124 (32.9) 128 (34.0) 167 (44.3) Recent MI (<6 months), n (%) 65 (17.3) 65 (17.2) 71 (18.8) 68 (18.0) Previous CABG, n (%) 23 (6.1) 11 (2.9) 15 (4.0) 18 (4.8) Previous TIA or stroke, n (%) 30 (8.0) 39 (10.3) 45 (11.9) 63 (16.7) Median screening SBP, mm Hg (IQR) (116.0, 144.0) (120.0, 145.0) (121.0, 151.0) (125.5, 159.5) < Median screening DBP, mm Hg (IQR) 70.0 (64.0, 79.0) 72.0 (64.0, 80.0) 71.0 (65.0, 80.0) 72.0 (62.5, 81.5) Median preop serum creatinine, mg/dL (IQR) 1.00 (0.85, 1.18) 1.00 (0.87, 1.13) 1.00 (0.87, 1.15) 1.02 (0.85, 1.21) < Median preop hemoglobin, g/dL (IQR) (12.70, 15.20) (12.91, 15.10) (12.60, 15.24) (11.80, 14.80) < Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

ECLIPSE Procedural Characteristics AUC Study Population (N=1507) Quartile 1 AUC 0– <0.09 (n=376) Quartile 2 AUC 0.09– <4.77 (n=377) Quartile 3 AUC 4.77– <26.21 (n=377) Quartile 4 AUC ≥26.21 (n=377) Median duration of surgery, h (IQR) 3.32 (2.60, 4.27) 3.30 (2.65, 4.00) 3.13 (2.53, 4.00) 3.33 (2.65, 4.25) Duration on pump, h (IQR) 1.48 (1.08, 2.00) 1.38 (1.08, 1.83) 1.35 (0.98, 1.73) 1.49 (1.12, 1.98) Type of primary surgical procedure, n (%) CABG263 (69.9) 287 (76.1) 288 (76.4) 276 (73.2) Valve repair or replacement 46 (12.2) 45 (11.9) 43 (11.4) 42 (11.1) CABG and valve repair42 (11.2) 26 (6.9) 24 (6.4) 35 (9.3) Other0 (0.0) 1 (0.3) Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

ECLIPSE Procedural Characteristics AUC Study Population (N=1507) Quartile 1 AUC 0– <0.09 (n=376) Quartile 2 AUC 0.09– <4.77 (n=377) Quartile 3 AUC 4.77– <26.21 (n=377) Quartile 4 AUC ≥26.21 (n=377) Type of repeat surgical procedure, n (%) CABG13 (3.5) 10 (2.7) 12 (3.2) Valve repair or replacement 8 (2.1) 3 (0.8) 5 (1.3) CABG and valve repair4 (1.1) 5 (1.3) 4 (1.1) 6 (1.6) Other0 (0.0) Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

Results Patients in Q4 (ie, the highest SBP excursions outside a specified range) were found to be at highest risk for 30-day adverse clinical outcomes Patients in Q4 (ie, the highest SBP excursions outside a specified range) were found to be at highest risk for 30-day adverse clinical outcomes The incidence of adverse outcomes increased as the AUC increased from Q1 to Q4 The incidence of adverse outcomes increased as the AUC increased from Q1 to Q4 –By Kaplan-Meier analysis, the 30-day risk of having an adverse clinical outcome was 8.8% Q1, 10.1% Q2, 10.1% Q3, and 14.4% Q4 –The risk of having an event was significantly greater in the Q4 group when compared with both the Q1 group (P=0.016) and the Q1 through Q3 groups combined (P=0.012) –Significantly fewer patients in Q4 were treated with CLV versus the comparators (P=0.0002) Q4 (CLV 157: comparators [CMP] 220) versus Qs 1 to 3 (CLV 594: CMP 536)Q4 (CLV 157: comparators [CMP] 220) versus Qs 1 to 3 (CLV 594: CMP 536)

Summary of 30-day Composite Outcome in Patients with Perioperative Hypertension Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

Summary of 30-day Composite Outcome in Patients with Perioperative Hypertension Aronson S., et. al. American Society of Anesthesiologists (ASA) 2008 Annual Meeting. October 18–22, 2008, Orlando, FL.

Conclusions Cardiac surgery patients with inadequate BP control are at increased risk of 30-day death, stroke, MI, and renal dysfunction compared with patients with tight BP control Cardiac surgery patients with inadequate BP control are at increased risk of 30-day death, stroke, MI, and renal dysfunction compared with patients with tight BP control CLV appears to offer superior BP control in surgical patients in this clinical setting CLV appears to offer superior BP control in surgical patients in this clinical setting CLV appears to offer superior perioperative BP control in cardiac surgery patients compared with the combined comparators SNP, NTG, and NIC as shown by the decreased number of patients in Q4 who were receiving CLV CLV appears to offer superior perioperative BP control in cardiac surgery patients compared with the combined comparators SNP, NTG, and NIC as shown by the decreased number of patients in Q4 who were receiving CLV –This observation requires further investigation in prospective, randomized clinical trials